Finance

Lists
086450:KOSDAQ
Dongkook Pharmaceutical Co Ltd
â‚©19,850.00
+1.17%
(+230.00) 1D
Sep 11, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 086450...
Open
â‚©19,400
High
â‚©20,300
Low
â‚©19,310
Mkt. cap
897.82B
Avg. vol.
499.06K
Volume
0.00
Dividend
1.01%
Quarterly dividend
â‚©50
Ex-dividend date
Dec 29, 2025
P/E ratio
11.70
52-wk high
â‚©31,250
52-wk low
â‚©16,260
EPS
â‚©1,697
Shares outstanding
45.23M
No. of employees
1K
Open
â‚©19,400
High
â‚©20,300
Low
â‚©19,310
Mkt. cap
897.82B
Avg. vol.
499.06K
Volume
0.00
Dividend
1.01%
Quarterly dividend
â‚©50
Ex-dividend date
Dec 29, 2025
P/E ratio
11.70
52-wk high
â‚©31,250
52-wk low
â‚©16,260
EPS
â‚©1,697
Shares outstanding
45.23M
No. of employees
1K
About Dongkook Pharmaceutical Co Ltd
CEOSong Jun-ho
Employees1.28K
FoundedOct 1968
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
226.81B
242.88B
251.02B
258.90B
Cost of goods sold
102.50B
110.08B
110.26B
115.10B
Cost of revenue
102.50B
110.08B
110.26B
115.10B
Research and development expenses
8.28B
8.80B
9.46B
8.69B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
88.07B
96.34B
100.54B
105.57B
Operating expense
99.51B
108.50B
113.42B
117.71B
Total operating expenses
202.01B
218.58B
223.68B
232.80B
Operating income
24.80B
24.30B
27.34B
26.09B
Other non operating income
3.51B
-1.85B
2.06B
-3.19B
EBT including unusual items
28.78B
17.81B
30.18B
23.32B
EBT excluding unusual items
28.79B
21.91B
32.75B
23.59B
Income tax expense
6.46B
2.23B
3.87B
6.08B
Effective tax rate
22.43%
12.50%
12.83%
26.07%
Other operating expenses
450.17M
429.71M
278.11M
465.66M
Net income
19.95B
13.85B
24.95B
17.55B
Net profit margin
8.80%
5.70%
9.94%
6.78%
Earnings per share
-
-
-
-
Interest and investment income
-
1.48B
2.84B
-
Interest expense
-
-412.07M
-1.01B
-
Net interest expenses
-
1.06B
1.83B
-
Depreciation and amortization charges
1.93B
2.03B
2.01B
2.27B
EBITDA
32.81B
32.62B
35.69B
34.94B
Gain or loss from assets sale
10.69M
57.84M
16.24M
269.61M
AI content may include mistakes. Learn more
Google apps